Results 1 to 10 of about 137,068 (205)

P-80 SEVERELY OBESE PATIENTS HAD HEPATIC FIBROSIS EVEN WITHOUT METABOLIC SYNDROME

Annals of Hepatology, 2021
Introduction: Metabolic Associated Fatty Liver Disease (MAFLD) is a clinic-pathological condition commonly associated with metabolic syndrome (MS) and this association is frequently found in severely obese. Objective: To compare clinical and histological
Carla Daltro, Ana Paula Berbeth-Casto, Luiz Antonio R de-Freitas, Antônio Ricardo Andrade, Helma P. Cotrim   +4 more
doaj   +1 more source

O-22 METABOLIC ASSOCIATED FATTY LIVER DISEASE: A SEVERE LIVER DISEASE

Annals of Hepatology, 2021
Background: The spectrum of metabolic associated fatty liver disease (MAFLD) includes steatosis, steatohepatitis, that can progress to cirrhosis, hepatocellular carcinoma, and to advanced stage of liver disease.
Ana Rafaela S. Do Vale, Andreza Rosa Cabral, Naiade S. Almeida, Antonio Ricardo C.F. Andrade, Ana Cristina Landim, Helma P. Cotrim   +5 more
doaj   +1 more source

O-23 METABOLIC ASSOCIATED FATTY LIVER DISEASE CLINICAL PROFILE IN LEAN PATIENTS: CAN IT BE DIFFERENT?

Annals of Hepatology, 2021
Background: The prevalence of metabolic associated fatty liver disease (MAFLD) in lean patients has grown around the world and the better understanding of this liver disease, in these individuals, has become of interest.
Andreza Rosa Cabral, Ana Rafaela S. Do Vale, Naiades S. Almeida, Raquel Rocha, Antonio Ricardo C.F. de Andrade, Ana Cristina Landin, Helma P. Cotrim   +6 more
doaj   +1 more source

P-83 RELEVANCE OF RENAL CHANGES IN A LARGE SERIES OF SEVERELY OBESE PATIENTS WITH METABOLIC ASSOCIATED FATTY LIVER DISEASE

Annals of Hepatology, 2021
Introduction: Metabolic associated fatty liver disease (MAFLD) is the most common cause of chronic liver disease worldwide. Recently, the relationship between MAFLD and chronic kidney disease has raised more interest because this relationship may be an ...
Kellyane Dias Carvalho, Carla Daltro, Claudia Daltro, Helma P. Cotrim   +3 more
doaj   +1 more source

A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies

Cells, 2021
5′AMP-activated protein kinase (AMPK) is known as metabolic sensor in mammalian cells that becomes activated by an increasing adenosine monophosphate (AMP)/adenosine triphosphate (ATP) ratio. The heterotrimeric AMPK protein comprises three subunits, each
Christian von Loeffelholz, Sina M. Coldewey, Andreas L. Birkenfeld   +2 more
doaj   +1 more source

Efficacy and Safety of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycholic Acid Combination in Chronic Hepatitis Related to Metabolic Syndrome Components

The Korean Journal of Gastroenterology, 2021
Backgrounds/Aims: Steatohepatitis related to metabolic syndrome is a chronic liver disease prevalent in patients not only with non-alcoholic steatohepatitis but also with alcoholic liver disease and chronic viral hepatitis.
Nae-Yun Heo, Seung Ha Park, Joon Hyuk Choi, Eunju Kim, Tae Oh Kim, Jongha Park, Jin Lee, Yong Eun Park, Eun Hye Oh, Jun Seong Hwang, Su Jin Jeon   +10 more
doaj   +1 more source

Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis [PDF]

, 2020
Background A non-invasive method to grade the severity of steatohepatitis and liver fibrosis is magnetic resonance imaging (MRI) based corrected T1 (cT1).
Banerjee, R, Banerjee, R, Bell, J.D., Bell, J.D., Hemingway, H., Hemingway, H., Hingorani, A.D., Hingorani, A.D., Kelly, M., Kelly, M., McGonigle, J., McGonigle, J., Neubauer, S., Neubauer, S., Nicholls, R.C., Nicholls, R.C., Parisinos, C.A., Parisinos, C.A., Patel, R.S., Patel, R.S., Thomas, E.L., Thomas, E.L., Wilman, H., Wilman, H., Yaghootkar, H., Yaghootkar, H.   +25 more
core   +3 more sources

The effect of 12 weeks regular physical activity and vitamin E in the treatment of non-alcoholic steatohepatitis: A pilot study [PDF]

, 2015
Background: Despite the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), there was no treatment has been proven to be effective in these common diseases.
Eslami, L., Isazadehfar, K., Karami, M., Eslami, L., Rahmani-nia, F., Nakhostinroohi, B.   +5 more
core   +7 more sources

Role of Leptin in Non-Alcoholic Fatty Liver Disease

Biomedicines, 2021
Non-alcoholic fatty liver disease (NAFLD), which affects about a quarter of the global population, poses a substantial health and economic burden in all countries, yet there is no approved pharmacotherapy to treat this entity, nor well-established ...
Carlos Jiménez-Cortegana, Alba García-Galey, Malika Tami, Pilar del Pino, Isabel Carmona, Soledad López, Gonzalo Alba, Víctor Sánchez-Margalet   +7 more
doaj   +1 more source

Animal models of NASH: getting both pathology and metabolic context right [PDF]

, 2015
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of referral to liver clinics, and its progressive form, non-alcoholic steatohepatitis (NASH), can lead to cirrhosis and end-stage liver disease.
Larter, Claire Z., Yeh, Matthew M.
core   +1 more source